Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Cerilliant
Boehringer Ingelheim
McKesson
Fish and Richardson
Federal Trade Commission
UBS
Cantor Fitzgerald
Covington
Chubb

Generated: February 25, 2018

DrugPatentWatch Database Preview

Procainamide hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for procainamide hydrochloride and what is the scope of procainamide hydrochloride freedom to operate?

Procainamide hydrochloride
is the generic ingredient in seven branded drugs marketed by Ascot, Idt Australia Ltd, Ivax Sub Teva Pharms, Lannett, Lederle, Roxane, Vangard, Watson Labs, Parke Davis, Panray, Apothecon, Abraxis Pharm, Hospira, Intl Medication, Nexus Pharms, Pharmafair, Smith And Nephew, Solopak, Warner Chilcott, West-ward Pharms Int, Ani Pharms Inc, Inwood Labs, Sandoz, Parkedale, and King Pharms, and is included in seventy NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for procainamide hydrochloride. Five suppliers are listed for this compound.
Pharmacology for procainamide hydrochloride
Drug ClassAntiarrhythmic
Medical Subject Heading (MeSH) Categories for procainamide hydrochloride

US Patents and Regulatory Information for procainamide hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 089027-001 Oct 22, 1985 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lannett PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 084696-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ivax Sub Teva Pharms PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 084595-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apothecon PRONESTYL-SR procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 087361-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 084280-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Vangard PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 087875-001 Jun 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apothecon PRONESTYL procainamide hydrochloride CAPSULE;ORAL 007335-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 087020-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Parke Davis PROCAN procainamide hydrochloride CAPSULE;ORAL 085804-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Parkedale PROCAN SR procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 086065-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for procainamide hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms PROCANBID procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 020545-002 Jan 31, 1996 ➤ Sign Up ➤ Sign Up
King Pharms PROCANBID procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 020545-001 Jan 31, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
AstraZeneca
Baxter
McKesson
Cerilliant
US Department of Justice
Chinese Patent Office
Fuji
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot